Navigation Links
Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
Date:7/14/2009

In addition to EZN/SPC2968 and EZN/SPC3042 Enzon has now received all the remaining six novel cancer drug candidates from Santaris Pharma and Enzon has announced the targets for four of these compounds: Her3, beta catenin, PIK3CA and the androgen receptor.

Pipeline Summary

In H1 2009 Santaris Pharma continued the progress for both the drug discovery programs and the drug development pipeline. At the end of June Santaris Pharma had four drugs in clinical development:

    - SPC3649, an LNA-antimiR(R) against microRNA-122, being
      developed for the treatment of HCV infections

    - EZN/SPC2968, a HIF-1alpha inhibitor, being developed for the
      treatment of various solid tumors

    - SPC2996, a Bcl-2 inhibitor, being developed for the
      treatment of cancer. Santaris Pharma has initiated the process of
      divesting this candidate

    - EZN3042, an LNA-based Survivin inhibitor, being developed
      for the treatment of various solid tumors

In addition to the four clinical development stage compounds Santaris Pharma and its partners have several other compounds in the discovery, research and preclinical stages, including the new apoB inhibitor, SPC4955 which now enters preclinical development and the PCSK9 lead candidates which are ready for pharmacological studies.

See Santaris Pharma's pipeline through this link: http://www.santaris.com/Library/documents/Santaris_Pharma_Interim_Report_1_Ja nuary_to_30_June_2009.pdf

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

Research

During H1 2009 Santaris Pharma and/or partners have published six scientific articles and more have been submitted
'/>"/>

SOURCE Santaris Pharma
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... immune system identifies the transplanted organ as foreign tissue ... cells, the immune cells that mediate rejection, must first ... to migrate to the transplanted organ. In this issue ... Lakkis and colleagues at the University of Pittsburgh used ... is not required for migration. Instead, these cells must ...
(Date:5/17/2013)... New interactive learning forums ... leaders of the medical device industry at the ... expo, from June 18-20 in Philadelphia ... ) , These all-new MedTech ... practical presentations and implementable solutions on the most ...
(Date:5/17/2013)... Miami, FL (PRWEB) May 17, 2013 Men’s ... at La-roche Posay ) and has been known ... itself. Although some men may be far from puberty, other ... be clogging pores, causing breakouts, and threatening skin with unsightly ... with advice from Men’s Health on how to ...
(Date:5/17/2013)... Tooth decay is an epidemic in American children with 50% ... World Health Organization says that worldwide, 60–90% of ... are the long-term effects of this transmissible infection? , ... oral bacterial imbalance and serious systemic issues like heart disease. ... also 100% preventable? Answer: there has been no way to ...
Breaking Biology Technology:MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... Expand Versatility of DelSite cGMP Polymer, ... (Pink Sheets: CARN) today announced its wholly-owned,subsidiary, ... rights license agreement with a biotechnology company ... DelSite,s,high-molecular-weight anionic polysaccharide which is produced under ...
... 19 /Xinhua-PRNewswire/ -- Shanghai Century (Amex:,SHA), a special ... Co., Ltd (Kelun), China,s largest producer of,intravenous (IV) ... highlights with respect to the consolidated results of,operations ... entity,(Kelun Group) for the first half of 2007. ...
... PARSIPPANY, N.J., Sept. 19 Over 20 new ... Biotech Competitive Intelligence &,Business Analysis" conference in two ... standard for pharmaceutical CI, Business Analysis, and Market,Forecasting ... gather on,October 1-2 to attend the meeting. Competition ...
Cached Biology Technology:Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines 2Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines 3Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 2Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 3Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 4Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 5New Competitive Intelligence Speakers Spark Interest in Pharmaceutical Conference on October 1-2 in NJ 2
(Date:5/17/2013)... Ill. An international team of ... structure and cell movement inside a living frog embryo ... a new method to advance biological research and the ... Northwestern University and the Karlsruher Institut fr Technologie in ... the U.S. Department of Energy,s Argonne National Laboratory, released ...
(Date:5/16/2013)... MARC (Maximizing Access to Research Careers) Program has ... for Developmental Biology (SDB) 72nd Annual Meeting in ... are meant to promote the entry of students, ... mainstream of the basic science community and to ... SDB 2013 Annual Meeting. , Awards are given ...
(Date:5/16/2013)... University scientists have shown a gene involved in neurodegenerative ... function of the circadian clock. , In a ... the gene, called Ataxin-2, keeps the clock responsible for ... gene, the rhythm of the fruit fly,s sleep-wake cycle ... difficult for the fly. , The discovery is ...
Breaking Biology News(10 mins):New X-ray method shows how frog embryos could help thwart disease 2Gene involved in neurodegeneration keeps clock running 2
... in the September issue of the Journal of Lipid ... a role in the rising rate of diabetes, especially in ... is the primary mechanism of inheritance; kids get half their ... just starting to understand additional kinds of inheritance like metabolic ...
... a group of University of Oklahoma researchers began studying ... has plagued the energy industry for decades, they did ... capable of converting hydrocarbons into natural gas. ... hydrocarbon metabolismcan be used to stimulate methane gas production ...
... received a $3.2 million grant from the National ... and mathematical disciplines to stem cell research. In ... experts in fields such as cell and molecular ... breakthroughs from the biology lab into practical and ...
Cached Biology News:OU researchers isolate microorganisms that convert hydrocarbons to natural gas 2OU researchers isolate microorganisms that convert hydrocarbons to natural gas 3$3.2M for Rutgers to apply biology, engineering, physical sciences toward stem cells 2$3.2M for Rutgers to apply biology, engineering, physical sciences toward stem cells 3
Mouse HAI-1 Ectodomain MAb (Clone 199732)...
pETDuet-1 is designed for the coexpression of two target genes....
Human IL-29/IFN-lambda 1 Biotinylated Affinity Purified PAb...
Mouse Laminin-1 MAb (Clone AL-3)...
Biology Products: